Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

977 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multicenter Real-World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with a Polatuzumab Vedotin-Based Regimen in a Compassionate Use Program in Malaysia.
Wahid SFA, Muhamad NA, Ismail NA, Rosli IA, Kien CS, Lim SM, Chew LP, Kamini K, Selvaratnam V, Kori AN, Seng TH, Ng SC. Wahid SFA, et al. Among authors: lim sm. Asia Pac J Clin Oncol. 2025 Jun 27:e14208. doi: 10.1111/ajco.14208. Online ahead of print. Asia Pac J Clin Oncol. 2025. PMID: 40576066
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Taher AT, Al-Samkari H, Aydinok Y, Besser M, Boscoe AN, Dahlin JL, De Luna G, Estepp JH, Gheuens S, Gilroy KS, Glenthøj A, Sim Goh A, Iyer V, Kattamis A, Loggetto SR, Morris S, Musallam KM, Osman K, Ricchi P, Salido-Fiérrez E, Sheth S, Tai F, Tevich H, Uhlig K, Urbstonaitis R, Viprakasit V, Cappellini MD, Kuo KHM; ENERGIZE investigators. Taher AT, et al. Lancet. 2025 Jun 19:S0140-6736(25)00635-X. doi: 10.1016/S0140-6736(25)00635-X. Online ahead of print. Lancet. 2025. PMID: 40544857
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial.
Cho BC, Lu S, Lee MA, Song Z, Park JJ, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Loong HH, Chen C, Wang J, Shen Y, Fan Z, Chen Q, Wang H, Zhang J, Chen ZJ, Johnson ML, Mok T. Cho BC, et al. Among authors: lim sm. Nat Med. 2025 Apr 29. doi: 10.1038/s41591-025-03688-6. Online ahead of print. Nat Med. 2025. PMID: 40301557
977 results